Table 1.
Unadjusted comparisons between patients receiving nintedanib therapy and patients under conventional medications.
| Factors | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| Nintedanib (36) | Non-nintedanib (115) | P-value | Nintedanib (35) | Non-nintedanib (87) | P-value | |
| Age (y) | 57.3 ± 10.0 | 56.0 ± 11.9 | 0.529 | 57.1 ± 10.1 | 56.5 ± 12.3 | 0.788 |
| Sex (male/female) | 14/22 | 41/74 | 0.725 | 14/21 | 30/57 | 0.566 |
| Clinical manifestations or comorbidities | ||||||
| Dysphagia | 4 (11.1%) | 19 (16.5%) | 0.430 | 3 (8.6%) | 12 (13.8%) | 0.624 |
| Dysarthria | 1 (2.8%) | 9 (7.8%) | 0.497 | 1 (2.9%) | 5 (5.7%) | 0.672 |
| Respiratory muscle involvement | 0 (0.0%) | 5 (4.3%) | 0.339 | 0 (0.0%) | 2 (2.3%) | 1.000 |
| Cardiac involvement | 4 (11.1%) | 4 (3.5%) | 0.174 | 4 (11.4%) | 3 (3.4%) | 0.103 |
| Gastrointestinal hemorrhage | 4 (11.1%) | 6 (5.2%) | 0.391 | 4 (11.4%) | 5 (5.7%) | 0.482 |
| Pulmonary bacterial infection | 6 (16.7%) | 31 (27.0%) | 0.210 | 6 (17.1%) | 23 (26.4%) | 0.275 |
| Pulmonary fungal infection | 0 (0.0%) | 5 (4.3%) | 0.339 | 0 (0.0%) | 3 (3.4%) | 0.557 |
| Carcinoma | 5 (13.9%) | 19 (16.5%) | 0.706 | 5 (14.3%) | 14 (16.1%) | 0.803 |
| UIP pattern | 9 (25.0%) | 26 (22.6%) | 0.767 | 8 (22.9%) | 20 (23.0%) | 0.988 |
| Pneumomediastinum | 1 (2.8%) | 6 (5.2%) | 0.878 | 1 (2.9%) | 4 (4.6%) | 1.000 |
| Survivala (m) | 4 (11.1%) | 38 (33.0%) | 0.015 | 4 (14.4%) | 30 (34.5%) | 0.016 |
| RP-ILD | 2 (5.6%) | 27 (23.5%) | 0.017 | 2 (5.7%) | 22 (25.3%) | 0.014 |
| Disease activity | ||||||
| MYOACT score | 8.0 (7.0, 9.0) | 8.0 (6.0, 10.0) | 0.635 | 8.0 (7.0, 9.0) | 8.0 (6.0, 10.0) | 0.649 |
| Lung function testing | ||||||
| FVC% (%) | 65.1 ± 16.4 | 70.8 ± 18.6 | 0.103 | 64.7 ± 16.4 | 70.4 ± 18.5 | 0.110 |
| TLC (L) | 3.6 ± 1.2 | 3.7 ± 1.0 | 0.465 | 3.5 ± 1.2 | 3.7 ± 1.0 | 0.535 |
| FEV1% (%) | 68.5 ± 16.5 | 72.3 ± 19.4 | 0.286 | 68.0 ± 16.6 | 71.4 ± 19.4 | 0.370 |
| FEV1/FVC | 0.8 (0.8, 0.9) | 0.8 (0.8, 0.9) | 0.218 | 0.8 (0.8, 0.9) | 0.8 (0.8, 0.9) | 0.105 |
| DLCO% (%) | 53.0 ± 20.8 | 60.6 ± 19.7 | 0.049 | 53.0 ± 21.1 | 58.1 ± 18.1 | 0.184 |
| Myositis-specific antibodies and myositis-associated antibodies | ||||||
| Anti-MDA5 | 9 (25.0%) | 25 (21.7%) | 0.683 | 9 (25.7%) | 21 (24.1%) | 0.855 |
| Anti-PL-7 | 3 (8.3%) | 16 (13.9%) | 0.553 | 2 (5.7%) | 13 (14.9%) | 0.272 |
| Anti-PL-12 | 1 (2.8%) | 4 (3.5%) | 1.000 | 1 (2.9%) | 3 (3.4%) | 1.000 |
| Anti-EJ | 3 (8.3%) | 6 (5.2%) | 0.775 | 3 (8.6%) | 4 (4.6%) | 0.408 |
| Anti-Ro-52 | 21 (58.3%) | 59 (51.3%) | 0.461 | 21 (60.0%) | 47 (54.0%) | 0.548 |
| Anti-Jo-1 | 5 (13.9%) | 21 (18.3%) | 0.544 | 5 (14.3%) | 19 (21.8%) | 0.342 |
| Anti-OJ | 2 (5.6%) | 2 (1.7%) | 0.241 | 2 (5.7%) | 2 (2.3%) | 0.578 |
| Anti-TIF1γ | 1 (2.8%) | 13 (11.3%) | 0.226 | 1 (2.9%) | 11 (12.6%) | 0.192 |
| Anti-Ku | 1 (2.8%) | 6 (5.2%) | 0.878 | 1 (2.9%) | 4 (4.6%) | 1.000 |
| Anti-SRP | 2 (5.6%) | 4 (3.5%) | 0.629 | 2 (5.7%) | 3 (3.4%) | 0.624 |
| Anti-NXP2 | 1 (2.8%) | 11 (9.6%) | 0.337 | 1 (2.9%) | 7 (8.0%) | 0.520 |
| Anti-PM-Scl75 | 3 (8.3%) | 9 (7.8%) | 1.000 | 3 (8.6%) | 6 (6.9%) | 1.000 |
| Anti-PM-Scl100 | 1 (2.8%) | 2 (1.7%) | 0.561 | 0 (0.0%) | 2 (2.3%) | 1.000 |
| Anti-Mi-2α | 3 (8.3%) | 6 (5.2%) | 0.775 | 3 (8.6%) | 2 (2.3%) | 0.142 |
| Anti-Mi-2β | 1 (2.8%) | 7 (6.1%) | 0.728 | 1 (2.9%) | 3 (3.4%) | 1.000 |
| Anti-SAE1 | 2 (5.6%) | 4 (3.5%) | 0.629 | 2 (5.7%) | 3 (3.4%) | 0.624 |
| Comorbidities/harmful hobbies | ||||||
| Smoking | 7 (19.4%) | 15 (13.0%) | 0.342 | 7 (20.0%) | 11 (12.6%) | 0.300 |
| Alcohol abuse | 7 (19.4%) | 23 (20.0%) | 0.942 | 7 (20.0%) | 16 (18.4%) | 0.837 |
| Hypertension | 10 (27.8%) | 15 (13.0%) | 0.038 | 9 (25.7%) | 14 (16.1%) | 0.219 |
| Diabetes | 8 (22.2%) | 18 (15.7%) | 0.362 | 8 (22.9%) | 15 (17.2%) | 0.473 |
| Hepatitis | 6 (16.7%) | 19 (16.5%) | 0.984 | 6 (17.1%) | 16 (18.4%) | 0.871 |
| Allergic history | 5 (13.9%) | 18 (15.7%) | 0.797 | 5 (14.3%) | 9 (10.3%) | 0.761 |
| Therapies | ||||||
| Steroid monotherapy | 7 (19.4%) | 28 (24.3%) | 0.543 | 7 (20.0%) | 21 (24.1%) | 0.623 |
| Steroid + DMARDs | 23 (63.9%) | 57 (49.6%) | 0.133 | 22 (62.9%) | 44 (50.6%) | 0.218 |
| Steroid + IVIG | 3 (8.3%) | 17 (14.8%) | 0.475 | 3 (8.6%) | 13 (14.9%) | 0.518 |
| Steroid + DMARDs + IVIG | 3 (8.3%) | 13 (11.3%) | 0.845 | 3 (8.6%) | 9 (10.3%) | 1.000 |
| Maximum dosage of steroidb | 50.0 (38.8, 100.0) | 75.0 (50.0, 100.0) | 0.112 | 50.0 (35.0, 100.0) | 75.0 (50.0, 100.0) | 0.139 |
| IIM subtypes | ||||||
| DM | 24 (66.7%) | 72 (62.6%) | 0.659 | 23 (65.7%) | 54 (62.1%) | 0.706 |
| PM | 7 (19.4%) | 29 (25.2%) | 0.478 | 7 (20.0%) | 21 (24.1%) | 0.623 |
| ADM | 5 (13.9%) | 14 (12.2%) | 1.000 | 5 (14.3%) | 12 (13.8%) | 1.000 |
y, years; m, months; UIP pattern, Usual interstitial pneumonia pattern; RP-ILD, Rapidly progressive interstitial lung disease; MYOACT, Myositis Disease Activity Assessment Visual Analog Scales; FVC%, Percent-predicted forced vital capacity; TLC, Total lung capacity; L, Liter; FEV1%, Percent-predicted forced expiratory volume in 1 s; FEV1/FVC, Ratio of FEV1 over FVC; DLCO%, Percent-predicted diffusing capacity of the lung for carbon monoxide; DMARDs, Disease-modifying anti-rheumatic drugs; IVIG, Intravenous immunoglobulin; IIM, Idiopathic inflammatory myopathy; DM, dermatomyositis; PM, Polymyositis; ADM, Amyopathic dermatomyositis.
a
Mortality in follow-up, P-value was calculated using Kaplan-Meier method with log-rank test.
b
Calculated by prednisolone.